Lazertinib European Commercialization Milestone Achieved, $30M Payment Received
-
Milestone achieved due to European commercialization start of lazertinib+amivantamab combination therapy licensed to Janssen
-
Expected milestone payment of $30,000,000 (approx. KRW 44.9 billion, 2.05% of consolidated revenue)
-
Invoice date: 2026-05-14, payment expected within 60 days
KOSPI Filing Information
-
Filing: Other Management Matters (Voluntary Disclosure)
-
Company: Yuhan (000100)
-
Submission: Yuhan Corporation
-
Receipt: 05-14-2026
-
Under KRX KOSPI Market Division